Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vaginosis Clear all
Active, not recruiting No phase listed Observational

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

NCT04713618
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Malignant Pelvic Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Pelvic Examination, Survey
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional

Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery

NCT00842452
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Vaginal Cancer, Vulvar Cancer
Interventions
topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
Steven Waggoner, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Internet-based System for Cancer Patients to Self-report Toxicity

NCT00578006
View directory record Official record
Conditions
Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions
Questioners, STAR website
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

NCT04079218
View directory record Official record
Conditions
HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions
Estradiol Vaginal Insert
Drug
Lead sponsor
Kerry Murphy
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Product 55394, Placebo Vehicle (non-treatment)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

NCT02209519
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Metronidazole (male partner), Placeob (male partner)
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pell City, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308046
View directory record Official record
Conditions
Vaginal Infection
Interventions
Terconazole, Placebo
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue

NCT01347632
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Discharge
Interventions
Metronidazole
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 29, 2026, 5:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort

NCT04885556
View directory record Official record
Conditions
Vaginal Discharge, Dyspareunia, Female Sexual Dysfunction, Vaginitis, Bacterial Vaginoses
Interventions
Tampon-like device for absorption of sexual fluids
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 29, 2026, 5:40 PM EDT
Terminated No phase listed Observational

ChemoFx® PRO - A Post-Market Data Collection Study

NCT00669422
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Effect of Flourish HEC Vaginal Care System on BV Recurrence and the Vaginal Microbiome

NCT05701722
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Flourish HEC Vaginal Care System
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 29, 2026, 5:40 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

NCT02316249
View directory record Official record
Conditions
Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions
Estradiol, placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

NCT01361048
View directory record Official record
Conditions
Trichomonas Vaginitis
Interventions
oral metronidazole, neo penotran forte, neo penotran forte once a day
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 29, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

NCT02466971
View directory record Official record
Conditions
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
377
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females

NCT01310582
View directory record Official record
Conditions
Ureteral Stent Occlusion, Exposure Laser, Ureterostomy; Functional Disturbance, Vaginal Diseases, Injury of Bladder, Excessive Repair, Calculi
Interventions
Desflurane, Sevoflurane
Drug
Lead sponsor
Hahnemann University Hospital
Other
Eligibility
60 Years to 85 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00083213
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 29, 2026, 5:40 PM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

LACTIN-V Study for Recurrent Bacterial Vaginosis

NCT02766023
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Lactobacillus crispatus CTV-05, Metronidazole, Placebo
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 29, 2026, 5:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Data Bank Creation to Study Vaginal Conditions

NCT01829204
View directory record Official record
Conditions
Vulvodynia, Mycoses, Bacterial Vaginosis, Preterm Labor
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Midland, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Relational Agents in Cervical Cancer Education (RACE)

NCT06537687
View directory record Official record
Conditions
Cervix Cancer, Human Papilloma Virus, Vaginal Cancer, Vulvar Cancer
Interventions
Control, Intervention
Other
Lead sponsor
Radhika Gogoi
Other
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 29, 2026, 5:40 PM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 29, 2026, 5:40 PM EDT